The article presents a clinical classification system for age-related macular degeneration (AMD) developed by a committee of 26 international experts. The classification system aims to standardize the description of AMD, improve communication among eye care providers, and facilitate research. The system is based on fundus lesions assessed within 2 disc diameters of the fovea in individuals over 55 years old. Key points include: 1. **Basic Clinical Classification**: A 5-stage classification scale is proposed, distinguishing normal aging changes from early AMD, which is characterized by small drusen (<63 μm, or "drupelets"), and intermediate AMD, which is associated with medium drusen (≥63–<125 μm) or pigmentary abnormalities. Late AMD is defined by neovascular AMD or geographic atrophy. 2. **Risk Estimation**: The 5-year risk of progressing to late AMD increases approximately 100-fold, ranging from 0.5% for normal aging changes to 50% for the highest intermediate AMD risk group. 3. **Consensus Development**: The classification system was developed using a modified Delphi process, where committee members rated statements on a 9-step scale, leading to consensus on the criteria for each stage of AMD. 4. **Clinical Relevance**: The proposed classification system is intended to improve communication and patient care, especially as new preventive interventions for AMD become available. 5. **Future Directions**: The committee plans to develop a scientific classification scheme using advanced imaging methods and psychophysical tests to address more detailed AMD phenotypes. The article emphasizes the importance of a standardized classification system for AMD, highlighting its potential to enhance research and clinical practice.The article presents a clinical classification system for age-related macular degeneration (AMD) developed by a committee of 26 international experts. The classification system aims to standardize the description of AMD, improve communication among eye care providers, and facilitate research. The system is based on fundus lesions assessed within 2 disc diameters of the fovea in individuals over 55 years old. Key points include: 1. **Basic Clinical Classification**: A 5-stage classification scale is proposed, distinguishing normal aging changes from early AMD, which is characterized by small drusen (<63 μm, or "drupelets"), and intermediate AMD, which is associated with medium drusen (≥63–<125 μm) or pigmentary abnormalities. Late AMD is defined by neovascular AMD or geographic atrophy. 2. **Risk Estimation**: The 5-year risk of progressing to late AMD increases approximately 100-fold, ranging from 0.5% for normal aging changes to 50% for the highest intermediate AMD risk group. 3. **Consensus Development**: The classification system was developed using a modified Delphi process, where committee members rated statements on a 9-step scale, leading to consensus on the criteria for each stage of AMD. 4. **Clinical Relevance**: The proposed classification system is intended to improve communication and patient care, especially as new preventive interventions for AMD become available. 5. **Future Directions**: The committee plans to develop a scientific classification scheme using advanced imaging methods and psychophysical tests to address more detailed AMD phenotypes. The article emphasizes the importance of a standardized classification system for AMD, highlighting its potential to enhance research and clinical practice.